ABSTRACT
Transcriptase Inhibitors ...................................................................................................... 371 19.4 Chromatographic Techniques for Monitoring of Nonnucleoside Reverse
Transcriptase Inhibitors ...................................................................................................... 375 19.5 Chromatographic Techniques for Monitoring of Protease Inhibitors ................................ 376 19.6 Chromatographic Techniques for Monitoring of Fusion Inhibitors ................................... 378 19.7 Chromatographic Techniques for Monitoring of Integrase Inhibitors ............................... 379 19.8 Chromatographic Techniques for Monitoring Multiple Classes of Drugs
in a Single Run .................................................................................................................... 379 19.9 Conclusions ......................................................................................................................... 381 References ...................................................................................................................................... 381
The year 2008 when this book chapter is being written marks the 27th anniversary of the discovery of the first reported case of a patient suffering from human immunodeficiency virus (HIV). In the beginning of reported HIV infections, only very few drugs were available in treating patients. Since then many new antiretroviral agents have been discovered and approved by the Federal Drug Administration (FDA) of the U.S. thus revolutionizing the antiretroviral therapy in treating patients with AIDS (Table 19.1). With the success of these medications in restoring immune function, now HIV infected patients can be managed like patients suffering from a chronic disease. Unfortunately, in developing countries only approximately 20% of patients have access to antiretroviral therapy, thus causing AIDS epidemic [1]. In highly active antiretroviral therapy (HAART); several drugs of
different class are used in combination to treat patients with HIV. Currently there are 25 approved drugs belonging to six different classes are available for treating patients with HIV infection [2].
